These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18368303

  • 1. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H.
    Clin Auton Res; 2008 Mar; 18 Suppl 1():19-24. PubMed ID: 18368303
    [Abstract] [Full Text] [Related]

  • 2. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
    Mathias CJ.
    Clin Auton Res; 2008 Mar; 18 Suppl 1():25-9. PubMed ID: 18368304
    [Abstract] [Full Text] [Related]

  • 3. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 4. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug 12; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R, Landsberg L, Young J.
    Neurology; 1999 Dec 10; 53(9):2151-7. PubMed ID: 10599797
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 10; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB.
    J Am Soc Hypertens; 2016 Oct 10; 10(10):755-762. PubMed ID: 27614923
    [Abstract] [Full Text] [Related]

  • 13. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb 10; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 14. The treatment of orthostatic hypotension with dihydroxyphenylserine.
    Freeman R, Landsberg L.
    Clin Neuropharmacol; 1991 Aug 10; 14(4):296-304. PubMed ID: 1913697
    [Abstract] [Full Text] [Related]

  • 15. Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions.
    Loavenbruck A, Sandroni P.
    Curr Med Res Opin; 2015 Nov 10; 31(11):2095-104. PubMed ID: 26373628
    [Abstract] [Full Text] [Related]

  • 16. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 17. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure.
    Kaufmann H, Oribe E, Yahr MD.
    J Neural Transm Park Dis Dement Sect; 1991 Oct 16; 3(2):143-8. PubMed ID: 1910486
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.
    J Parkinsons Dis; 2016 Oct 19; 6(4):751-759. PubMed ID: 27636856
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.